Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study shows superior response rate of Abraxane in women with metastatic breast cancer
December 29th, 2005
American Pharmaceutical Partners, Inc. (APPX) and American BioScience, Inc., announced that the Journal of Clinical Oncology published data from the pivotal phase III clinical trial pertaining to efficacy, safety and survival associated with Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer. The paper, titled "Superior Efficacy of Albumin-Bound Paclitaxel, ABI-007, Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Metastatic Breast Cancer," was released early online. The significance of early online publications as characterized by the journal is that...
Source: Women's Health Weekly (2005-12-29)
|
